Gilead Sciences (NASDAQ:GILD) disappointed investors when it announced 2018 fourth-quarter earnings in February. The big biotech badly missed the consensus analysts' earnings estimate.
On Thursday, Gilead reports its latest quarterly results after the market closes. Here are three things you can expect in the biotech's Q1 earnings update.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,